Kraig Biocraft Laboratories works with local cooperative to expand Mulberry production in Quang Nam, Vietnam

Plans to add nearly 2,500 acres of mulberry to support commercialization scale of up of the Company’s recombinant spider silk technology

ANN ARBOR, Mich., – June 26, 2018 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers announces today that the Company’s representatives in Quang Nam province, Vietnam are working, in collaboration with a local cooperative, to expand mulberry production.   This effort is a major element of the Company’s production expansion plans and marks a significant increase in capacity. 

News of this collaboration was recently published in a leading Vietnamese digital media outlet, which highlights the efforts to focus on high technology agriculture and re-energize the Vietnamese share of the multi-billion dollar sericulture industry.  Expanding mulberry production in Quang Nam, by nearly 2,500 acres, is a powerful step to increasing total silk production and a key component of the Company’s plan to bring its spider silk technology to market.

“Collaboration with local farmers and workers, leveraging their expertise and knowledge, is core to our production scale up efforts,” said Jon Rice COO.  “This effort highlights the complementary efforts that we are taking, in combination with the leadership in Quang Nam, to restore their traditional sericulture industry, by blending in new high technology agriculture. This continued collaboration will play a key part in the exciting growth potential we’re seeing with our expansion in Vietnam and the market for affordable spider silk materials.”

Original Source Article

http://thoibaokinhdoanh.vn/hop-tac-xa/quang-nam-htx-lien-ket-voi-cong-ty-my-dau-tu-nganh-dau-tam-1048434.html

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories produces first roll of pure Dragon Silk fabric for U.S. Army

ANN ARBOR, Mich., – June 21, 2018 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers announces today that it has just finished the production of its first roll of pure Dragon Silk fabric, marking the first time that the Company’s proprietary recombinant spider silk fibers were used to create a 100% pure woven silk fabric.

The Company is now preparing to assemble the Dragon Silk material into finalized ballistic shoot packs, per the U.S. Army specifications.  This materials is destined for ballistic performance testing, under the Company’s contract with the U.S. Army, to evaluate its potential for protective apparel applications.

“Dragon Silk, which started as a simple idea in the lab for a better performing silk, is now on the verge of demonstrating its capability to provide lifesaving performance blended with high flexibility and user comfort,” said Jon Rice COO.  “What a proud moment for the Company and all of our employees, as we prepare to process this first roll of Dragon Silk fabric into test samples for the U.S. Army and to assess its ability to assist in protecting the brave men and women of our armed forces, who dedicate themselves to protecting all of us.”

The Company previously developed sample products, in pure and blended knit configurations using its Monster Silk materials, including shirts and gloves.  Today’s announcement marks the first time the Company’s newer and stronger Dragon Silk will be transitioned into an end product.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

 

This entry was posted on by .

Kraig Biocraft Laboratories deploys new Spider Silk DNA synthesis methodology

More than 2,500 test microinjections completed with expanded lab staff to boost throughput

ANN ARBOR, Mich., – June 12, 2018 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers announces today that the Company has completed more than 2,500 microinjections using the recently announced new spider silk DNA synthesis methodology.  This new method allows for faster creation of larger and more complex spider silk proteins.  Larger and more complex proteins are believed to produce improved silk strength, toughness, and elasticity.  These improved recombinant spider silk fibers will allow the Company to target an expanded set of end market applications.

To support this expanded research and development capability, the Company added two laboratory staff for increased testing throughput.  The additional lab staff members have been trained and have conducted the majority of the microinjection effort.

By implementing this new validated protocol and completing these initial microinjections, the Company is looking forward to creating new transgenics, at Kraig Labs’ U.S. R&D headquarters, with an abridged development cycle and enhanced materials performance.  The transgenics created using the new protocols are expected to be transitioned into Prodigy Textiles’, the Company’s recently announced Vietnamese subsidiary, commercial production process.  

“Thanks to our lab and production teams’ considerable collaborative effort, this new methodology has already demonstrated the potential to significantly reduce our development timelines. To see it put into practice so quickly and to have already completed the first 2,500 test microinjections is very impressive,” said Jon Rice, COO.  “I look forward to seeing this capability enable the next generation of recombinant spider silk fibers.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

 

This entry was posted on by .

Kraig Biocraft Laboratories develops new breakthrough Spider Silk DNA Synthesis Protocols accelerating time to market for new products

Kraig Labs’ R&D team raises the bar in transgenic research

ANN ARBOR, Mich., – May 23, 2018 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that its R&D team has achieved a major breakthrough in the construction of DNA encoding for spider silk proteins. 

With this new capability the Company believes that it should be able to reduce the customization timeframe, for new spider silk technologies, by several months.

The new protocols were developed after Kraig Labs reached out to leading DNA synthesis facilities, which all stated that construction of the desired sequences would be practically impossible, due to the unique structure of spider silk proteins.  Refusing to accept that answer, Kraig’s research team then took on the task directly. 

Using a combination of distinct approaches, Kraig Labs successfully synthesized the highly complex set of spider silk protein construct designs.  This new approach should accelerate the pace of its research and production rollout efforts, as well as reduce costs to develop new transgenics for new potential markets and applications. 

The newly designed protein constructs are currently being prepared for incorporation into the Company’s spider silk platform technology.  Due to their construction, these new designs may have the potential to produce new silk fibers with even greater strength and flexibility than the Company’s current generation of recombinant spider silk. 

“Today’s announcement is another in a long history of Kraig Labs proving the impossible, possible,” said Jon Rice, COO.  “From our first transgenic silkworms, to the creation of Monster Silk and then Dragon Silk, to obtaining approvals for international expansion, the Company has proven, time and time again, that we have the tenacity to reimagine what is possible. These new constructs and the ability to rapidly adapt them could open new and wider applications in military and high performance technical textile markets.  Today we celebrate yet another example of how the Company is changing the rules in biotech development.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

 

This entry was posted on by .

Kraig Biocraft Laboratories takes next steps in Prodigy Textiles’ Spider Silk Commercialization program

Increased transgenic egg production and staffing of new operations among its New Vietnamese Subsidiary’s next steps

ANN ARBOR, Mich., – May 14, 2018 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers provides an update on progress towards the commercialization of spider silk technology following last week’s announcement of the formation of its Vietnamese subsidiary, Prodigy Textiles Co,. Ltd (“Prodigy”).  The Company views Prodigy as its main production arm for spider silk technologies.

The Company is gearing up production of its proprietary spider silk silkworm eggs in preparation for shipment to Prodigy.  These Silkworms are slated to be the first transgenics produced at Prodigy.

Kraig Labs has identified a facility, in Quang Nam province, with the capacity to support operations and is working with local experts to update and buildout the facility to meet production specifications.    

To bring Prodigy production operations online, Kraig Labs has accelerated Prodigy’s staffing and hiring plans.  Key technical and administration positions within Prodigy have been identified and the Company is working with its consultants in Vietnam to fill these positions. 

Company management is now preparing to travel to Vietnam to oversee Prodigy’s launch, where they will also be oversee hiring core staff, the transfer of the Company’s spider silk silkworm technology, and the beginning of operations. 

“Momentum at Prodigy is growing and we’re focused on the exciting milestones ahead,” said Jon Rice, COO.  “We are busy preparing silkworm eggs for shipment and putting the team in place at Prodigy to hit the ground running.  We are now taking concrete steps to build on all the work we’ve done in Vietnam and to convert that into a thriving operation for spider silk production.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

 

This entry was posted on by .

Kraig Biocraft Laboratories Granted Long Sought License for Business Operations in Vietnam; Prepares for Grand Opening

Issuance of License seen as the most significant commercial event in the biotechnology Company’s development of spider silk based materials

ANN ARBOR, Mich., – May 1, 2018 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, is very happy to announce today the positive result of its five years of working with the Vietnamese government at both the central and provincial levels: The Company has been issued its long awaited Enterprise Registration Certificate (ERC) required to begin its operations in Vietnam.

“These licenses to operate in a traditional silk producing region are the most substantial milestones for Kraig Labs commercial development since the creation of our first spider silk transgenics,” said Kraig Labs Founder and CEO, Kim Thompson. “Our teams in the U.S.A. and in Vietnam have been working closely with officials in Quang Nam province and with central government ministries to bring this long standing vision to reality.”

The Company’s advanced silk production platform was designed specifically to fit within and utilize existing silk industry infrastructure. The Company’s systems were designed that way in order to provide what the Company believes to be a significant and nearly insurmountable competitive advantage. “Our work to obtain these approvals has been driven by our goal of producing recombinant spider silk on a large scale, which can only be achieved by harnessing the opportunities presented by existing large scale silk production infrastructure,” stated Thompson.

 

The Company has already proven through its contract with the U.S. Army that its spider silk technology can be scaled quickly and efficiently, moving from the laboratories of the University of Notre Dame and into its own research and production facilities. We are now on a path to scale our product to much greater levels, by harnessing existing silk production infrastructure with the capacity to match the demand for our spider silk materials.

 

“Today’s announcement is more than just a major milestone for the Company, it’s a revolutionary step in the commercialization of spider silk,” said Jon Rice, Kraig Labs’ COO. “More than five years of hard work, meetings, and extensive legal and regulatory paperwork, have gone into securing these approvals and licenses. We now stand ready to change an entire industry.”

“This is a historic moment for Kraig Labs and for all of our shareholders who have taken part in this journey with us. Our shareholders know how much time, effort and resources have been expended to reach this goal and for the Company to walk through this exciting threshold,” Thompson concluded.

 

Today’s announcement follows closely on the heels of last week’s announcement of the formation of the Company’s Vietnamese subsidiary Prodigy Textiles Co., Ltd., and the receipt of that subsidiary’s Investment Registration Certificate (IRC). Having been issued both its IRC and with today’s announcement, its Enterprise Registration Certificate (ERC), Prodigy Textiles Co., Ltd. is preparing to begin operation. The issuance of these critical licenses mark a major milestone for Kraig Biocraft Laboratories and the commercialization of spider silk.

 

Kraig considers its new wholly owned subsidiary, Prodigy Textiles Co., Ltd., to be its spider silk production arm. Vietnam has been the focus of the Company’s efforts to launch commercial scale production of recombinant spider silk, due to the country’s existing silk production infrastructure. Kraig estimates that it can produce its recombinant spider silk at prices similar to mundane silk, giving the Company a tremendous competitive advantage.

 

The Company is now preparing for the grand opening of its subsidiary operations in Quang Nam province, Vietnam. Management is preparing to hire staff for the new facilities and is prepping the first allotment of transgenic silkworms to ship from its U.S. research headquarters.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implicatio

ns for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include 

descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Announces Registration of New Vietnamese Subsidiary, Prodigy Textiles Co. Ltd

New subsidiary created as Company’s production arm for large scale Spider Silk production

ANN ARBOR, Mich., – April 24, 2018 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has received approval for the establishment of its new Vietnamese subsidiary, Prodigy Textiles Co. Ltd.  The Company is happy to announce it has received, from Vietnam, its official investment registration certificate for the new subsidiary.  The establishment of the Company’s first subsidiary is seen by management as a major milestone toward its long term goal of establishing large scale spider silk production. 

Vietnam has been the focus of the Company’s efforts to launch commercial scale production of recombinant spider silk, due to the country’s existing silk production infrastructure.  The Company’s advanced silk production platform was designed specifically to fit within and utilize existing silk industry infrastructure.  The Company’s systems were designed that way in order to provide what its founder and CEO, Kim Thompson, believes to be a significant and nearly insurmountable competitive advantage.

While the establishment of Prodigy Textiles Co. Ltd. is viewed by the Company as a major milestone toward commercialization and large scale production, establishing production in Vietnam requires a separate government issued enterprise registration certificate. 

“What a great moment for Kraig Labs and the entire Spider Silk industry.  We anticipate that our new subsidiary in Vietnam will open the doors and pave the way for spider silk production and our commercialization efforts,” said Thompson.  “I want to thank our COO, Jon Rice, and our exceptional team of professional consultants who have worked tirelessly to make the founding of this production arm of our Company a reality.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

 

 

This entry was posted on by .

Kraig Biocraft Laboratories releases a statement regarding Spider Silk Industry

As the Company prepares for commercialization of its engineered spider silk, Kraig Labs shares information on the developing industry.

ANN ARBOR, Mich., –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, releases the following statement regarding developments in the growing Spider Silk Industry.

Spider silk’s toughness is said to be 10 times greater than steel and some silks are nearly as elastic as rubber.  According to some studies, spider silks can be two to three times tougher than even Kevlar, which explains why so many researchers have targeted this fiber for protective clothing and body armor applications, as well as other potential military applications including technical undergarments and more practical ropes.

Numerous scientific studies have highlighted spider silk’s many intrinsic qualities and why it may be the ideal fiber for a slew of applications.  For example, spider silk’s maximal resilience, or ability to absorb energy, makes it one of the sturdiest materials on a weight-to-weight basis. These properties could make spider silk the foundation for many lightweight products, including air bags, seat belts, flexible bridge suspension cables, sports helmets and motor vehicle panels.

Additionally, studies have shown spider silk to be antimicrobial, biocompatible, hypoallergenic and totally biodegradable. Spider silk is a biomaterial that could be the platform on which to develop many medical technologies, like better bandages, elastic ligaments, and artificial tendons and even biodegradable water bottles.

Concurrent to Kraig Labs positioning for commercial production of its advanced fibers, many independent scientific studies have shown great promise in a vast array of potential spider silk applications.  The Company would like to congratulate all efforts that advance spider silk technologies.  A few recent examples of that work are provided below.  Each of these reports is entirely unaffiliated with Kraig Labs, and we therefore have not and cannot authenticate any specific conclusions. 

As noted in the linked report, just the chronic wounds, such as bedsores in hospitalized patients, afflict 6.5 million in the United States for an estimated $25 billion annually. The Company believes that the various scientific discoveries in the spider silk space were instrumental in seeing over $300 million in funding flow into spider silk platform development over the past few years. One of the Company’s current competitors is approaching $196 million in aggregate funding, including $106 million in 2017, potentially valuing that pre-production technology at more than $1 billion dollars, when applying a commonly used valuation formula.

http://www.kblbinvestors.com/new-breakthroughs/

“As Kraig Labs prepares to transition into commercial production, we plan to expand our R&D focus and, given the tremendous interest in spider silk, we believe that we will have many great opportunities to grow newly discovered application into new business lines with strong growth potential. As we initiate a process to explore further scientific alliances our objective is to help maximize the future value of Kraig Labs,” stated Kim Thompson, Kraig Labs’ CEO and Founder. 

Industrial applications may include flexible bridge suspension cables, better fishing nets and unrippable paper. Spider silk’s well-balanced combination of strength and elasticity may even be combined with graphene to create the next generation of metamaterials.

Under funding from the US Army Research Office and the National Science Foundation professor Xinwei Wang at Iowa State University published a paper on Spider silks ability to conduct heat as well or better than most materials, including very good conductors such as silicon, aluminum and pure iron.  That discovery reportedly “opens a door for soft materials to be another option for thermal conductivity tuning,” as stated by professor Wang in the above reference publication.  This may inspire better semiconductors and lead to the creation of flexible, heat-dissipating parts for electronics, microchips, better clothes for hot weather, bandages that don’t trap heat and many other everyday applications.

By designing a high performance fiber, based on a proven efficient and ecologically friendly production platform, the Company’s objective is to target a broad cross section of applications in the $160 billion (projected) technical fibers market and the budding smart textile markets.  The Company intends to also target the mundane markets, like active wear and the $5 billion raw silk fibers market, which have tighter pricing elasticity.

 “It’s very exciting to think that we may be positioned to focus our efforts and resources on participating in advancing some of the many researchers who approach us to employ our fibers for various potential mechanical applications and we’re looking forward to collaborations that could open a new realm of possibilities for our technology,” said Jon Rice, Kraig Labs’ COO.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories’ new R&D Facility extends its competitive advantages and prepares for large scale production

New larger Hybrid Cocoons provide production excitement

ANN ARBOR, Mich., –  April 11, 2018 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces follow up to its recently introduced new Hybrid Spider Silk Silkworm Cocoons, which were produced at the Company’s new research and development facility.

Development for the new hybrid was completed in-house, at Kraig Labs R&D facility using its Dragon Silk colony silkworms and a commercial mundane silkworm strain, which resulted in an estimated 100% increase in cocoon weight, compared to the cocoons that the Company was producing just four months ago in Indiana.

The Company understood that silkworms have been producing mundane silk for thousands of years and, that by employing the existing sericulture infrastructure, as well as expertise and traditions, it can cost effectively scale-up its transgenic spider silk silkworm production. According to Kraig Labs’ data, the Company should be able to commercialize some of the toughest natural fibers for almost the same cost as normal every day silk.

Eight countries produce the majority of world’s silk today, all of which have the resources and expertise to bring the Company’s fibers to market through mass production.  These countries have the potential to play a part in expanding Kraig Labs’ production footprint.

The Company believes that the new hybrid cocoons, along with its first recombinant spider silk producing silkworms and the development of Dragon Silk, are among the biggest sericulture breakthroughs in modern history.  As such, it’s important that the host countries respect Intellectual Property.  This is one of the reasons that Kraig Labs is looking at the potential of launching production in Vietnam.

“When I originally set out on the journey to mass produce spider silk, I knew that there were multiple production platform options.  Each of the obvious production platforms had serious shortcomings, including most importantly, an inability to produce spider silk at an acceptable price point.  I focused on inserting silkworms with the relevant gene sequence because silkworms have proven to be economically efficient and commercially viable natural silk producers.  In my opinion, silkworm remains the only economically viable platform,” stated Kim Thompson, Kraig Labs’ CEO and Founder.  “Kraig Labs’ R&D facility is a powerful tool to help us achieve optimum fiber and business performance,” Thompson concluded.

The activity in our industry has recently increased dramatically; most notably, multiple companies reportedly having raised over $300 million in combined funding to produce synthetic silks, which require chemicals and other steps to create their product. While these companies have interesting technological approaches, we believe, they lack the cost effectiveness of our silkworm based technology.  In our opinion, those approaches have no real way to commercialize spider silk in a way that takes advantage of the properties that make spider silk special, or at price points that are competitive with mundane silk.

 “Our production optimization initiatives are vital steps in the drive towards cost structure optimization and our new cocoons have shown us that even the most efficient fiber making process that exists in the world today, can be improved. A 100% increase in cocoon size from our existing products without any increased labor is a substantial win for our shareholders,” said Jon Rice, Kraig Labs’ COO.

We have posted our cost analysis on the existing market, and believe it confirms our ability to lead in this space, and why our excitement is growing to begin our first large scale production.  For further details concerning Kraig Labs’ cost advantages and comparative analysis, please go to www.kraiglabs.com/comparison

The Company is updating production plans and will update the shareholders and other interested parties when appropriate.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

 

 

This entry was posted on by .

Kraig Biocraft Laboratories Successfully Produces Recombinant Spider Silk Cocoons from New Line of Hybrid Silkworms

ANN ARBOR, Mich., – April 3, 2018- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company has successfully produced the first recombinant spider silk cocoons from the new line of hybrid transgenic silkworms recently created at its Michigan production and research facility.  This new hybrid line was created by combining one of the Company’s best performing recombinant spider silk lines with a commercial strain, resulting in the largest cocoons in the Company’s history. 

The first generation cocoons from this hybrid cross have exceeded the Company’s expectations with some cocoons nearly twice as large as the original spider silk line cocoons.  These larger cocoons reduce operating and handling costs throughout the production process and yield longer silk threads.  Mechanical performance testing of this new hybrid spider silk line is expected to begin shortly. 

“Crossing our recombinant spider silk silkworm lines with larger traditional silkworm lines is an element of both our research roadmap and commercialization plans.  The results we’ve seen from this first crossing confirm the benefits of those strategies,” said Jon Rice, COO.  “The size of these new hybrids is beyond what we expected in a first generation hybrid and we are very interested to see how performance testing results compare to the original silkworm lines.  We anticipate creating many additional hybrids, over the coming quarters, combining the performance of our spider silk lines with these larger commercial strains.  We expect these efforts will increase our production efficiency and lower our cost to produce recombinant spider silk.”

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

 

This entry was posted on by .